NCT07178249View on ClinicalTrials.gov

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

February 28, 2028

Study Completion Date

December 30, 2032

Conditions

Wet Age-related Macular Degeneration

Interventions

BIOLOGICAL

EXG202 injection

EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration（wAMD） with a single intravitreal injection and administration.

All Listed Sponsors

lead

Hangzhou Jiayin Biotech Ltd

INDUSTRY

NCT07178249 - Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD | Biotech Hunter | Biotech Hunter